In 2024, Giovannuzzi et al. designed and synthesized a series of dual inhibitors targeting brain hCAs and Monoamine Oxidase B (MAO-B), with the aim of modulating multiple pathological pathways implicated in Alzheimer’s disease and preventing β-amyloid (Aβ-42)-associated neurotoxicity [49]. This evidence concerns the gene MAOB and early-onset autosomal dominant Alzheimer disease.